Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 14, 2003Neurology

Neutralizing antibodies during treatment of secondary progressive MS with interferon β-1b

View Full Paper
Ask AI
Bookmark
Share

Authors

CPChris H. PolmanUniversity of SienaLKLudwig KapposUniversity of BaselRWRick WhiteUniversity of British Columbia

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Polman et al. (2003) studied this question.

synapsesocial.com/papers/6ab33d2a6e718c783360dd5fhttps://doi.org/10.1212/wnl.60.1.37
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis1993 · 2,093 citations
  2. 2Interferon beta‐lb in the treatment of multiple sclerosis1995 · 918 citations
  3. 3PRISMS-4: Long-term efficacy of interferon-β-1a in relapsing MS2001 · 569 citations
  4. 4Final analysis of the European multicenter trial on IFNβ-1b in secondary-progressive MS2001 · 145 citations
  5. 5Development of Neutralizing Antibodies in Patients with Relapsing-Remitting Multiple Sclerosis Treated with IFN-β1a1998 · 74 citations